SI1912640T1 - Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma - Google Patents
Uporaba inhibitorja hdac panobinostata za zdravljenje mielomaInfo
- Publication number
- SI1912640T1 SI1912640T1 SI200631952T SI200631952T SI1912640T1 SI 1912640 T1 SI1912640 T1 SI 1912640T1 SI 200631952 T SI200631952 T SI 200631952T SI 200631952 T SI200631952 T SI 200631952T SI 1912640 T1 SI1912640 T1 SI 1912640T1
- Authority
- SI
- Slovenia
- Prior art keywords
- myeloma
- treatment
- hdac inhibitor
- inhibitor panobinostat
- panobinostat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70522605P | 2005-08-03 | 2005-08-03 | |
EP06789025.1A EP1912640B1 (en) | 2005-08-03 | 2006-08-01 | Use of the hdac inhibitor panobinostat for the treatment of myeloma |
PCT/US2006/029801 WO2007019116A1 (en) | 2005-08-03 | 2006-08-01 | Use of hdac inhibitors for the treatment of myeloma |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1912640T1 true SI1912640T1 (sl) | 2015-10-30 |
Family
ID=37307336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200631952T SI1912640T1 (sl) | 2005-08-03 | 2006-08-01 | Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma |
Country Status (18)
Country | Link |
---|---|
US (2) | US20080221126A1 (sl) |
EP (1) | EP1912640B1 (sl) |
JP (2) | JP5665271B2 (sl) |
KR (1) | KR101354237B1 (sl) |
CN (2) | CN101232880A (sl) |
AU (1) | AU2006278718B2 (sl) |
BR (1) | BRPI0614090A2 (sl) |
CA (1) | CA2617274C (sl) |
DK (1) | DK1912640T3 (sl) |
ES (1) | ES2545076T3 (sl) |
HU (1) | HUE028025T2 (sl) |
LT (1) | LTC1912640I2 (sl) |
MX (1) | MX2008001610A (sl) |
PL (1) | PL1912640T3 (sl) |
PT (1) | PT1912640E (sl) |
RU (1) | RU2420279C3 (sl) |
SI (1) | SI1912640T1 (sl) |
WO (1) | WO2007019116A1 (sl) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE028025T2 (en) * | 2005-08-03 | 2016-11-28 | Novartis Ag | Use of Panobinostat HDAC inhibitor to treat myeloma |
EP2491923A3 (en) * | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
JP2010529028A (ja) * | 2007-05-30 | 2010-08-26 | ノバルティス アーゲー | 骨破壊の処置のためのhdac阻害剤の使用 |
WO2010075286A1 (en) * | 2008-12-24 | 2010-07-01 | University Of Washington | MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY |
CN103079551A (zh) * | 2010-09-01 | 2013-05-01 | 诺华有限公司 | Hdac抑制剂与血小板减少症药物的组合 |
MA41544A (fr) * | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
EP3371195B1 (en) | 2015-11-03 | 2021-04-21 | Hochschule Darmstadt | Selective hdac8 inhibitors and their uses |
CN105348169B (zh) * | 2015-11-16 | 2018-03-30 | 青岛大学 | 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用 |
CN109705057B (zh) * | 2017-10-25 | 2023-05-30 | 成都先导药物开发股份有限公司 | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
JP2021530504A (ja) | 2018-07-18 | 2021-11-11 | ヒルストリーム・バイオファーマ・インコーポレイテッド | サリノマイシンを含む高分子ナノ粒子 |
WO2022251844A1 (en) | 2021-05-25 | 2022-12-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising chemotherapeutic compounds and related methods |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
JP4477303B2 (ja) * | 2001-05-16 | 2010-06-09 | ノバルティス アーゲー | N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
AU2002361022A1 (en) | 2001-12-07 | 2003-06-17 | Novartis Ag | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
WO2004103358A2 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
CN101856348A (zh) * | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | 联合治疗癌症的方法 |
WO2006102557A2 (en) | 2005-03-22 | 2006-09-28 | The President And Fellows Of Harvard College | Treatment of protein degradation disorders |
HUE028025T2 (en) * | 2005-08-03 | 2016-11-28 | Novartis Ag | Use of Panobinostat HDAC inhibitor to treat myeloma |
-
2006
- 2006-08-01 HU HUE06789025A patent/HUE028025T2/en unknown
- 2006-08-01 BR BRPI0614090-4A patent/BRPI0614090A2/pt not_active Application Discontinuation
- 2006-08-01 EP EP06789025.1A patent/EP1912640B1/en active Active
- 2006-08-01 KR KR1020087002803A patent/KR101354237B1/ko active Protection Beyond IP Right Term
- 2006-08-01 PL PL06789025T patent/PL1912640T3/pl unknown
- 2006-08-01 AU AU2006278718A patent/AU2006278718B2/en not_active Ceased
- 2006-08-01 SI SI200631952T patent/SI1912640T1/sl unknown
- 2006-08-01 JP JP2008525092A patent/JP5665271B2/ja active Active
- 2006-08-01 CN CNA2006800281244A patent/CN101232880A/zh active Pending
- 2006-08-01 CA CA2617274A patent/CA2617274C/en active Active
- 2006-08-01 US US11/996,323 patent/US20080221126A1/en not_active Abandoned
- 2006-08-01 WO PCT/US2006/029801 patent/WO2007019116A1/en active Application Filing
- 2006-08-01 CN CN201410610419.9A patent/CN104324025A/zh active Pending
- 2006-08-01 MX MX2008001610A patent/MX2008001610A/es active IP Right Grant
- 2006-08-01 RU RU2008107871A patent/RU2420279C3/ru not_active IP Right Cessation
- 2006-08-01 PT PT67890251T patent/PT1912640E/pt unknown
- 2006-08-01 ES ES06789025.1T patent/ES2545076T3/es active Active
- 2006-08-01 DK DK06789025.1T patent/DK1912640T3/en active
-
2010
- 2010-03-04 US US12/717,373 patent/US8883842B2/en active Active
-
2013
- 2013-04-04 JP JP2013078867A patent/JP5876435B2/ja active Active
-
2016
- 2016-01-22 LT LTPA2016003C patent/LTC1912640I2/lt unknown
Also Published As
Publication number | Publication date |
---|---|
EP1912640A1 (en) | 2008-04-23 |
US8883842B2 (en) | 2014-11-11 |
EP1912640B1 (en) | 2015-06-17 |
CN101232880A (zh) | 2008-07-30 |
MX2008001610A (es) | 2008-02-19 |
LTC1912640I2 (lt) | 2017-09-11 |
KR101354237B1 (ko) | 2014-01-22 |
AU2006278718B2 (en) | 2010-10-07 |
BRPI0614090A2 (pt) | 2011-03-09 |
KR20080031937A (ko) | 2008-04-11 |
JP2009503087A (ja) | 2009-01-29 |
RU2008107871A (ru) | 2009-09-10 |
CA2617274C (en) | 2017-10-10 |
CA2617274A1 (en) | 2007-02-15 |
JP5665271B2 (ja) | 2015-02-04 |
US20100160257A1 (en) | 2010-06-24 |
PL1912640T3 (pl) | 2015-11-30 |
AU2006278718A1 (en) | 2007-02-15 |
WO2007019116A1 (en) | 2007-02-15 |
PT1912640E (pt) | 2015-09-22 |
RU2420279C2 (ru) | 2011-06-10 |
ES2545076T3 (es) | 2015-09-08 |
JP2013173757A (ja) | 2013-09-05 |
DK1912640T3 (en) | 2015-09-14 |
US20080221126A1 (en) | 2008-09-11 |
CN104324025A (zh) | 2015-02-04 |
HUE028025T2 (en) | 2016-11-28 |
JP5876435B2 (ja) | 2016-03-02 |
RU2420279C3 (ru) | 2017-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1912640T3 (pl) | Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka | |
AP2870A (en) | Odcase inhibitors for the treatment of malaria | |
IL183938A0 (en) | Amino - imidazolones for the inhibition of ?? - becretase | |
HK1124320A1 (en) | Sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles | |
HRP20130810T1 (en) | Sulphonylpyrroles as hdac inhibitors | |
LT2295410T (lt) | Hdac inhibitorius | |
ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
EP1898834A4 (en) | SELF-ADJUSTABLE ENDO-URETRAL DEVICE AND METHODS OF USE | |
IL189659A0 (en) | Ikk inhibitors for the treatment of endometriosis | |
EP2049505A4 (en) | ISOFORM SELECTIVE HDAC HEMMER | |
EP1965824A4 (en) | METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228 | |
PT2056814E (pt) | Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase | |
EP1888056A4 (en) | USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS | |
GB0624187D0 (en) | HDAC inhibitors | |
ZA201100165B (en) | Use of hdac inhibitors for the treatment of hodgkin's disease | |
GB0515035D0 (en) | Treatment of atherosclerotic conditions | |
IL201466A0 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
PT1962913E (pt) | Radioimunoconjugado para cd66 humano para o tratamento de mieloma múltiplo | |
GB0602857D0 (en) | The treatment of sialorrhoea | |
IL201439A0 (en) | Use of hdac inhibitors for the treatment of melanoma | |
ZA200906906B (en) | Use of HDAC inhibitors for the treatment of melanoma | |
EE200800070A (et) | HDAC inhibiitorite kasutamine lmfoomide raviks | |
GB0621474D0 (en) | Composition for the treatment of halitosis | |
ZA200801707B (en) | IKK inhibitors for the treatment of endometriosis |